Add BrightSurf on Google Email

SFU researchers develop new chemical biological tools to monitor Parkinson’s disease

Researchers at SFU have developed new chemical biological tools to monitor Parkinson’s disease progression, measuring the activity of lysosomal glucocerebrosidase (GCase) enzyme. This breakthrough could lead to improved diagnostics and treatment, as well as a better understanding of other neurodegenerative diseases linked to GCase.

SourceSimon Fraser University·JournalProceedings of the National Academy of Sciences·DateJul 13, 2022

UBC Okanagan study determines psychedelic mushroom microdoses can improve mood, mental-health

A UBC Okanagan study published in Nature-Scientific Reports found that regular small amounts of psilocybin improved mood, mental health, and psychomotor ability in participants. Microdosing was associated with reduced symptoms of depression, anxiety, and stress, particularly among those over 55.

SourceUniversity of British Columbia Okanagan campus·JournalNature·TypeRandomized controlled/clinical trial·DateJul 11, 2022

Addressing global disparities in Parkinson disease

The article discusses global disparities in Parkinson disease, identifying six key areas for improvement: disease burden, advocacy and awareness, prevention and risk reduction, diagnosis, treatment, and care, caregiver support, and research. These findings aim to inform policy decisions and drive action towards reducing health inequities.

SourceJAMA Network·JournalJAMA Neurology·DateJul 11, 2022

HBP scientists have simulated how the Parkinson’s brain responds to deep stimulation at multiple scales

Researchers used microcircuit models of basal ganglia and thalamus areas to create multiscale models of Parkinson's patient and healthy control brain. They found that in-silico deep brain stimulation could normalize decreased firing rates in subcortical regions, but also caused differential activity in the motor cortex.

SourceHuman Brain Project·JournalExperimental Neurology·TypeComputational simulation/modeling·DateJun 22, 2022

Investigators identify a new candidate therapeutic target for Parkinson’s disease

Researchers at Brigham and Women's Hospital have identified LIPE, a lipase that degrades triglycerides, as a promising candidate therapeutic target for Parkinson's disease. Inhibiting LIPE reduced alpha-synuclein inclusions and alleviated neurodegeneration in patient-derived neurons and a C. elegans model of toxicity.

SourceBrigham and Women's Hospital·Journalnpj Parkinson s Disease·TypeExperimental study·DateJun 9, 2022

Investigators discover a ‘double life’ for a key Parkinson’s disease protein

A study led by Brigham and Women's Hospital investigators has revealed that alpha-synuclein plays a dual role in Parkinson's disease, interacting with both vesicles and P-body structures. This new understanding may lead to targeted treatments for the disease, with ongoing genetic studies aiming to identify optimal therapeutic targets.

SourceBrigham and Women's Hospital·JournalCell·TypeExperimental study·DateJun 9, 2022

First-ever elucidation of a small protein’s structure could signal help for those with epilepsy and other disorders

Researchers at USC Dornsife College of Letters, Arts and Sciences have elucidated the structure of a small protein carrying GABA into neurons using cryogenic electron microscopy. This breakthrough could lead to more effective drugs for conditions such as epilepsy, bipolar disorder, schizophrenia, Parkinson's disease, and autism spectru...

SourceUniversity of Southern California·JournalNature·TypeImaging analysis·DateJun 8, 2022

World-first: A biomarker that can diagnose Parkinson’s disease

Researchers at Kobe University and Hiroshima University have developed a biomarker that can diagnose Parkinson's disease from blood serum samples. The 'P450 inhibition assay' uses 12 different human P450s to detect changes in metabolites, allowing for accurate diagnosis with an accuracy rate of 85-88%. This breakthrough could lead to f...

SourceKobe University·JournalScientific Reports·TypeExperimental study·DateMay 31, 2022

‘Sting’ protein’s efforts to clean up brain cell damage may speed Parkinson’s disease progress

A Johns Hopkins Medicine study found that a protein called STING responds to clean-up signals in brain cells damaged by Parkinson’s disease by creating a cycle of inflammation that accelerates the disease’s progression. In mice with deactivated STING proteins, there was less microglial activity and brain cell death.

SourceJohns Hopkins Medicine·JournalProceedings of the National Academy of Sciences·DateMay 19, 2022

Study in mice suggests that COVID-19 increases risk of developing Parkinson’s disease

A recent study published in Movement Disorders suggests that COVID-19 may increase the risk of developing Parkinson's disease by making brain cells more susceptible to damage. Researchers found that mice infected with SARS-CoV-2 were more likely to exhibit characteristic features of Parkinson's disease after exposure to a toxin.

SourceThomas Jefferson University·JournalMovement Disorders·TypeExperimental study·DateMay 18, 2022

Circuit model may explain how deep brain stimulation treats Parkinson’s disease symptoms

A new circuit model provides an explanation for how deep brain stimulation (DBS) relieves Parkinson's disease motor symptoms by interrupting a vicious cycle between the subthalamic nucleus and the striatum. The model suggests that DBS restores a balance with other rhythm frequencies, enabling better movement control.

SourcePicower Institute at MIT·JournalProceedings of the National Academy of Sciences·TypeComputational simulation/modeling·DateMay 16, 2022

Designer neurons offer new hope for treatment of Parkinson’s disease

Researchers have developed a process to convert non-neuronal cells into functioning neurons that can take up residence in the brain and restore capacities undermined by Parkinson's destruction of dopaminergic cells. In a proof-of-concept study, one group of experimentally engineered cells performs optimally in terms of survival, growth...

SourceArizona State University·Journalnpj Regenerative Medicine·TypeExperimental study·DateMay 11, 2022

Involving patients with Parkinson’s disease in research benefits everyone

The authors of a Call to Action emphasize the value of incorporating patient perspectives in clinical Parkinson's disease studies and recommend how to include patient researchers effectively. Patient involvement can help design better studies, ensure tolerable protocols, and improve research outcomes. However, specific challenges must ...

SourceIOS Press·JournalJournal of Parkinson’s Disease·TypeCommentary/editorial·DateMay 10, 2022

‘Stressed’ cells offer clues to eliminating build-up of toxic proteins in dementia

Researchers at the University of Cambridge have identified a new mechanism that appears to reverse the build-up of aggregates in neurodegenerative diseases, such as Alzheimer's and Parkinson's. By stressing cells, they found that protein misfolding was eliminated, potentially allowing for the refolding of correctly folded proteins.

SourceUniversity of Cambridge·JournalNature Communications·TypeExperimental study·DateMay 6, 2022

Dopamine involved in recognizing emotions

Research suggests dopamine is involved in emotion recognition, particularly in low-dose individuals. Dopamine levels influence emotional perception, with lower levels improving emotional recognition while higher levels impairing it. This finding has implications for understanding social cognition impairments in neurological disorders.

SourceSociety for Neuroscience·JournalJNeurosci·TypeExperimental study·DateMay 2, 2022

UTHealth Houston’s UTMOVE program receives distinguished Edmond J. Safra Fellowship in Movement Disorders

UTHealth Houston's UTMOVE fellowship program has been chosen by The Michael J. Fox Foundation for Parkinson's Research to train a new generation of movement disorder specialists. The two-year program will provide fellows with comprehensive training in diagnosing and treating Parkinson's disease, as well as opportunities for research an...

Novel deep learning method provides early and accurate differential diagnosis for Parkinsonian diseases

A new deep learning method, PDD-Net, uses 3D deep convolutional neural networks to extract deep metabolic imaging indices from PET scans for differential diagnosis of parkinsonian diseases. The method achieved high sensitivity and specificity rates for Parkinson's disease and other parkinsonian syndromes.

SourceSociety of Nuclear Medicine and Molecular Imaging·JournalJournal of Nuclear Medicine·DateApr 21, 2022

Deep brain stimulation driven by motor cortical activity can effectively treat Parkinson’s disease

Researchers developed a new method of deep brain stimulation driven by motor cortical activity to treat Parkinson's disease. This approach, known as adaptive DBS (aDBS), uses γ2 band activity from the primary motor cortex to modulate stimulation parameters and reduce battery consumption.

SourceNational Institutes of Natural Sciences·JournalScientific Reports·TypeExperimental study·DateApr 20, 2022

A doctor’s visit from the future

A doctor's visit from the future describes patient care in 2042, where diagnosis and treatment are personalized based on individual biological abnormalities. Researchers believe this approach could lead to more effective treatments for neurodegenerative disorders.

SourceUniversity of Cincinnati·JournalThe Lancet Neurology·DateApr 20, 2022

Electronic implant reactivates spinal-cord nerves of a patient with neurodegenerative disease

A groundbreaking system implanted directly on the spinal cord has restored blood pressure regulation in a patient with multiple system atrophy-parkinsonian type (MSA-P), enabling them to walk again after being bedridden for over a year. This innovative therapy paves the way for new clinical breakthroughs in treating degenerative diseases.

SourceEcole Polytechnique Fédérale de Lausanne·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateApr 6, 2022

Wireless pain management for drug-resistant conditions offers promising alternative to surgery, study finds

A new wireless implant has the potential to treat neuropathic pain resistant to medical therapy, offering a minimally invasive alternative to surgery. The device uses bioelectronic therapy to stimulate peripheral nerves from within blood vessels, providing precise placement and predictable outcomes.

SourceUniversity of Texas Health Science Center at Houston·JournalNature Biomedical Engineering·DateMar 31, 2022

Firing it up

A team at Harvard Medical School identified a mechanism that triggers local dopamine release in the brain when acetylcholine binds to axons, not previously known to initiate firing. This finding reveals more about the interaction between acetylcholine and dopamine systems, suggesting a new strategy for treating diseases like Parkinson's.

SourceHarvard Medical School·JournalScience·TypeImaging analysis·DateMar 24, 2022

Shining a light on protein aggregation in Parkinson’s disease

A novel system to control protein aggregation in a model of Parkinson’s disease suggests that aggregation of alpha-synuclein plays a critical role in disrupting neuronal homeostasis and triggering neurodegeneration. Light treatment led to formation of Lewy body-like aggregates, neurodegeneration, and Parkinson-like motor deficits in mice.

SourcePLOS·JournalPLOS Biology·TypeExperimental study·DateMar 22, 2022

Huddersfield scientists first to show how coronavirus triggers immune response in brain

Researchers at the University of Huddersfield have identified a key mechanism by which the coronavirus causes inflammation in the brain's immune cells, potentially explaining some symptoms experienced by COVID-19 patients. The study suggests that adequate funding is needed to further develop this research and its potential applications.

SourceUniversity of Huddersfield·JournalMolecular Neurobiology·TypeObservational study·DateMar 17, 2022